V-Erb-B2 erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/glioblastoma Derived Oncogene Homolog (Avian) (ERBB2) (C-Term) antibody

Details for Product No. ABIN499802
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, Erbb-2, Neu, c-erbB2, c-neu, mKIAA3023
Epitope
C-Term
(62), (52), (49), (46), (42), (38), (35), (28), (25), (23), (21), (16), (11), (9), (9), (9), (9), (9), (9), (9), (9), (9), (9), (8), (8), (8), (8), (8), (7), (7), (7), (7), (7), (6), (6), (6), (6), (6), (6), (6), (6), (6), (6), (6), (6), (6), (6), (5), (5), (4), (3), (3), (3), (3), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human, Mouse (Murine), Rat (Rattus)
(808), (331), (226), (91), (60), (48), (36), (24), (6), (4), (4), (2)
Host
Chicken
(670), (199), (16), (11), (5), (1)
Clonality
Polyclonal
Conjugate
Un-conjugated
(48), (38), (31), (24), (22), (20), (10), (10), (10), (10), (10), (10), (10), (10)
Application
ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
(472), (308), (220), (204), (166), (151), (104), (100), (60), (46), (43), (10), (5), (3), (2), (1), (1), (1), (1), (1), (1)
Pubmed 5 references available
Quantity 0.1 mg
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN499802
401.50 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen erbB-2 antibody was raised against a 19 amino acid peptide near the carboxy terminus of human erbB-2.
Isotype IgG
Specificity This antibody reacts to erbB-2.
Purification Affinity chromatography purified via peptide column
Alternative Name CD340 / ERBB2 / HER2
Background The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.
Alternate names: HER-2, MNL19, NEU, NEU proto-oncogene, NGL, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erbB-2, p185erbB2
Gene ID 2064
NCBI Accession NP_004439
UniProt P04626
Application Notes ELISA. Western Blot: 1 – 2 μg/ml. Immunohistochemistry. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Buffer PBS containing 0.02% sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C
Storage Comment Store the antibody undiluted at 2-8°C.
Expiry Date 12 months
Background publications Slamon, Clark, Wong et al.: "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene." in: Science (New York, N.Y.), Vol. 235, Issue 4785, pp. 177-82, 1987 (PubMed).

Marmor, Skaria, Yarden: "Signal transduction and oncogenesis by ErbB/HER receptors." in: International journal of radiation oncology, biology, physics, Vol. 58, Issue 3, pp. 903-13, 2004 (PubMed).

Manno: "Measurement of the digit lengths and the anogenital distance in mice." in: Physiology & behavior, Vol. 93, Issue 1-2, pp. 364-8, 2008 (PubMed).

Vermeij, Teugels, Bourgain et al.: "Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers." in: BMC cancer, Vol. 8, pp. 3, 2008 (PubMed).

Baselga, Swain: "Novel anticancer targets: revisiting ERBB2 and discovering ERBB3." in: Nature reviews. Cancer, Vol. 9, Issue 7, pp. 463-75, 2009 (PubMed).

Validation Images
Did you look for something else?
back to top